A 1-lactamase-stable antibiotic, the oral penem FCE 22891 (ritipenem acoxil), was investigated for use in exacerbations of chronic obstructive pulmonary disease (COPD). Thirteen Exacerbations of chronic obstructive pulmonary disease (COPD) are often caused by viral and bacterial infections, which are the most common causes of death in patients with this disease (5). The three major pathogens isolated from sputum specimens from COPD patients during an exacerbation are Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. In the past decade an increasing resistance to ampicillin due to production of P-lactamase has been recorded for H. influenzae (15 to 30%) (10, 11, 13) andM.
Exacerbations of chronic obstructive pulmonary disease (COPD) are often caused by viral and bacterial infections, which are the most common causes of death in patients with this disease (5). The three major pathogens isolated from sputum specimens from COPD patients during an exacerbation are Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. In the past decade an increasing resistance to ampicillin due to production of P-lactamase has been recorded for H. influenzae (15 to 30%) (10, 11, 13) andM.
catarrhalis (up to 85%) (8, 10, 22) . When the choice of treatment is empiric, especially in seriously ill patients, the agent should be directed against these P-lactamase-producing bacteria (17) .
The penem FCE 22891 (ritipenem acoxil) can be orally administered and is hydrolized in the intestine into its active moiety, FCE 22101 (7) . FCE 22101 is active against staphylococci (including some methicillin-resistant Staphylococcus aureus strains), streptococci, anaerobes (including Bacteroides species), and gram-negative aerobic bacteria, particularly the 3-lactamase-producing strains (17, 18, 24) , but it has little or no activity against Pseudomonas aeruginosa (24) . The (20) .
Symptoms were assessed before, during (days 4 and 8), and after (day 11) treatment and during follow-up (day 18) by the same investigator (S.P.). The severity of symptoms (dyspnea, cough, rales, signs of bronchial obstruction, and sputum production) was scaled from 0 to 2 (absent, mild, and severe). Sputum samples were examined and given a score of 0 (absent), 1 (mucous), 2 (Fig. 1) . Cure or marked improvement (reduction in .50% of the symptoms) was observed in eight patients (53%) by the end of treatment (day 11) and in six patients (40%) during follow-up (day 18). None of the patients were assessed as treatment failures.
All patients had a moderate to severe bronchial obstruction on admission; the FEV1 was 37.5 ± 4.3% (mean ± standard error of the mean). During antibiotic treatment (day 0 to day 11), the FEV1 did not improve significantly (P = 0.10), in contrast to the FEV1 (P = 0.02) between the start of treatment and follow-up (day 18) (Fig. 2) . The role of antibiotics in managing exacerbations of COPD is still controversial, because a spectrum of infectious and noninfectious agents may be involved in the pathogenesis of these exacerbations (3). Yet it seems unjustified to withhold antibiotics in COPD patients with severe or moderately severe exacerbations, especially since insufficient data on this issue are available (16) .
During the past decade a number of new antibiotics with activity against 1-lactamase-producing bacteria have been developed. One of these, FCE 22101, and its oral prodrug FCE 22891 have excellent activities against respiratory pathogens producing 13-lactamases, except for P. aeruginosa (4, 6, 9) .
In the present study, symptom scores and lung function improved especially during the first days of treatment. Whether the beneficial effect was due to FCE 22891 can only be speculated upon, since all COPD patients were concomitantly using bronchodilators and anti-inflammatory drugs. Speculation is emphasized by the observation that the recovery (14, 21, 23) . By the end of treatment and during follow-up the original pathogens, including resistant H. influenzae strains, were eradicated in 11 of 13 patients. In other studies, bacteriological efficacy was found in 76 to 100% of the cases (12, 14, 21) . Not all patients included in these studies had a positive sputum culture yielding respiratory pathogens (12, 14, 21) . Nevertheless, for diverse clinical reasons the treating physicians (noninvestigators) in this study prescribed another antibiotic in five cases. In these cases the comedication was not changed. Sputum cultures of both representative and nonrepresentative specimens from four of these patients yielded no pathogens prior to the institution of alternative antibiotic treatment. The high frequency of occurrence of FCE 22101-resistant H. influenzae strains was remarkable and has been recorded in only one other in vitro activity study (9) .
The adverse effect most frequently registered was gastrointestinal disturbance; in one patient this was so severe that the antibiotic had to be discontinued. Such gastrointestinal symptoms were also recorded in studies with both healthy volunteers and COPD patients (1). These gastrointestinal disturbances are probably not dose related, because no difference in adverse effects was found in patients using 250 mg three times a day and those using 1,000 mg three times a day (14) . These symptoms may be due to the effect of FCE 22891 on the intestinal flora. From this study it can be concluded that FCE 22891 has only a moderate efficacy in treating bacterial exacerbations in COPD patients and that the drug causes gastrointestinal symptoms with a high degree of frequency. This study was supported by a grant from Farmitalia Carlo Erba.
